Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple...…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial evaluating intranasal…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw Lucid Capital Markets raise its 12-month price target on the company to $9 from…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that updated data from its Expanded Access Program showed intranasal foralumab continued…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) reported PET imaging results from two patients in a Phase 2 Multiple System Atrophy trial…
…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday a late-breaking poster on its Phase 2a study of intranasal foralumab in…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new preclinical data suggesting that its investigational therapy, intranasal foralumab, may offer a...…
…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that a peer-reviewed study of its experimental intranasal therapy for secondary progressive…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has closed an $8.8 million equity financing backed by its senior leadership…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the pricing of a registered direct offering expected to raise up to approximately…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has submitted its seventh annual Development Safety Update Report (DSUR) to the…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about a series of important developments for the company, including…
…
…
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Wednesday it has dosed the first patient in a Phase 2 clinical trial…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has begun enrolling participants in its Phase 2 randomized, placebo-controlled clinical trial...…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it plans to spin out its anti-IL-6 receptor antibody program, TZLS-501, into…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral...…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday it has been invited to present at a major biotechnology conference in Riyadh,…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose more than 10% in late morning trading on Thursday after the biotech company said it plans to advance...…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said that its experimental nasal treatment for Alzheimer’s disease showed promising results in a patient,…
…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has initiated patient dosing at the Weill Cornell Medicine Multiple Sclerosis Center…
Tiziana Life Sciences Ltd (NASDAQ:TLSA)’ investigational therapy intranasal foralumab has been shown to significantly reduce neuroinflammation in a...…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Friday that a patient with moderate Alzheimer’s disease showed a marked reduction in…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the University of Massachusetts has commenced dosing patients in its ongoing Phase 2…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the University of Massachusetts has commenced dosing patients in its ongoing Phase 2…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that Johns Hopkins University has begun dosing patients in its Phase 2 clinical…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it has begun dosing patients at Yale MS Center in its multicenter…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a groundbreaking study in Nature Neuroscience that demonstrates promising results...…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it expects to complete its preclinical study evaluating its nasal anti-CD3 foralumab as…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced a new agreement with Renaissance Lakewood LLC to advance the development of its…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that additional patients with non-active secondary progressive multiple sclerosis (na-SPMS) have been...…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its investigational drug, intranasal foralumab, is gaining attention for its potential to address Alzheimer’s...…
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced positive results from studies of a nasal anti-CD3 monoclonal antibody in traumatic spinal…